صحة
صحة
Ready to play
Ready to play
A study led by researchers at Queen Mary University of London found that treating 14 people with primary aldosteronism with baxdrostat for 6 to 12 months was associated with improvements that lasted for up to two years after they stopped taking it. The aldosterone-to-renin ratio remained about 99% below its pretreatment level, and blood pressure fell by an average of approximately 25 mmHg. Around a quarter of participants reached normal levels without additional medication. However, the study was small and does not prove that the treatment leads to a lasting cure. Researchers are conducting further studies to investigate its effects on aldosterone-producing cells. The drug requires medical monitoring because it may raise potassium levels or lower sodium levels. Its current U.S. approval is for treating uncontrolled high blood pressure—not for demonstrating a cure after treatment is stopped.
Notice: This Is an AI-Generated Summary
Comments (0)